Shire To Present Additional Scientific Data On ADHD Treatment Portfolio At American Psychiatric Association Annual Meeting
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.
Sensory Treatment Reduces Autistic Mannerisms
Parents of children with autism are increasingly turning to sensory integration treatment to help their children deal with the disorder, and they're seeing good results. In 2007, 71 percent of parents who pursued alternatives to traditional treatment used sensory integration methods, and 91 percent found these methods helpful.
Auriga Laboratories Obtains Rights To Market And Sell A New Product Indicated For The Treatment Of ADHD
Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company, announced today the signing of a license agreement with Outlook Pharmaceuticals, Inc., pursuant to which Auriga will have the exclusive rights to market and sell a new product indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the United States.
Studies Review Smoking Among College Freshmen And Tobacco Use By Adolescents With ADHD
A supplemental issue of Nicotine and Tobacco Research published yesterday includes a variety of key findings on the smoking habits of college freshmen; nicotine dependence; the use of tobacco by individuals with attention- deficit/ hyperactivity disorder, depression and anxiety;
The Significant Impact of Adult ADHD On Social, Financial And Personal Aspects Of Life
Nationally recognized Attention Deficit Hyperactivity Disorder (ADHD) authority Russell Barkley, Ph.D., has embarked on a national speaking tour to discuss the symptoms of ADHD in adults and the potentially serious consequences these symptoms may have on the life of an adult living with this disorder.
Additional Dosage Strengths Of Vyvanse Approved By FDA
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for three additional dosage strengths for the attention deficit hyperactivity disorder (ADHD) treatment, VYVANSE™
Attention Seeking Confused With ADHD
Teachers and parents need to beware of confusing children who are attention seeking with those who suffer from attention-deficit hyperactivity disorder (ADHD).This is the finding of Dr Nigel Mellor an independent Educational Psychologist who presented his research on Thursday 10 January 2008, at the British Psychological Society's Division of Child and Educational Psychology Annual Conference in Bournemouth.
Finding The Causes Of ADHD - New Study Launched By Norwegian Institute Of Public Health
An unprecedented ADHD study was launched on Wednesday 16th January to find causes and early warning signs of ADHD among pre-school age children. ADHD is frequently diagnosed but little is known about the causes, despite all the published research. Today there are no diagnostic criteria for ADHD in children under 6 years of age.
SpeechWorks Debuts New Autism ADHD Therapy In Columbia
SpeechWorks is one of 30 providers internationally that offer the Sensory Learning Program, an innovative 30-day program geared towards correcting sensory issues in the brain. The program combines three conventional therapies into one, and it's showing progress not just for Autism, but for kids with learning disabilities, attention deficit disorder and developmental delays.
Study Raises Questions About Diagnosis, Medical Treatment Of ADHD
A new UCLA study shows that only about half of children diagnosed with attention-deficit hyperactivity disorder, or ADHD, exhibit the cognitive defects commonly associated with the condition. The study also found that in populations where medication is rarely prescribed to treat ADHD, the prevalence and symptoms of the disorder are roughly equivalent to populations in which medication is widely used.